| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Alzheimer's disease (AD) is the major cause of dementia. To clarify the pathogenesis and development of disease modifyed drugs (DMD) of AD, we studied effects of oral immunization of recombinant soybean consisting of Abeta epitope (Abeta+) in AD model mice TgCRND8. Induction of anti-Abeta antibodies, prevention of memory decline and Abeta plaque accumulation. Abeta oligomer was also suppressed. No adverse reactions were observed. Thus, Abuta+ is promissing DMT. In study of Hirosaki Family, we found 43 AD patients out of total 285 family members, mean onset age is 48 years of Age and duration is about 10 years.
|
